PharmaLogic Acquires Majority Stake in Agilera to Expand Radiopharmaceutical CDMO Platform

• PharmaLogic has completed its acquisition of a majority stake in Agilera Pharma AS from IFE in Norway.

• The move expands PharmaLogic’s radiopharmaceutical CDMO operations and global distribution network.

PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) focused on radiopharmaceuticals, has finalised its acquisition of a majority stake in Norway-based Agilera Pharma AS. The stake was acquired from the Institute for Energy Technology (IFE).

The deal marks a key development in PharmaLogic’s strategy to create a fully integrated, global CDMO platform dedicated to radiopharmaceutical therapeutics. Agilera brings established manufacturing and development expertise, with a distribution network spanning more than 30 countries.

Etienne Montagut, President and CEO of PharmaLogic, said: “The addition of Agilera’s capabilities to PharmaLogic marks a key milestone in our expansion strategy into radiopharmaceutical therapeutics.”

The acquisition expands PharmaLogic’s operational footprint and service offering across clinical and commercial stages, bolstering its ability to deliver end-to-end contract manufacturing and development support for radiopharmaceutical products.